A biocide testing system includes test columns, a bypass tube, control valves, and a control system. Each test column includes biocide test coupons. The bypass tube is fluidly coupled to each of the test columns. Each control valve is coupled between a respective test column and the bypass tube. The control system performs operations including: controlling the control valves to fluidly couple the test columns to a water source; controlling a pump to circulate water from the water source into the test columns to immerse each test coupon in water; controlling the control valves to fluidly isolate the test columns from the water source and to fluidly isolate each test column from the other test columns; controlling a particular control valve to fluidly couple a particular test column to a biocide source; and controlling the pump to circulate biocide from the biocide source into the particular test column to immerse the test coupons in the particular test column in biocide.

The current invention concerns a new B. subtilis strain with strong inhibition of C. perfringens and its use as a probiotic.

The invention provides genetically modified non-human animals that express a humanized MHC II protein (humanized MHC II α and β polypeptides), as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.

The present description relates to chimeric bacteriophage lysins useful for the identification and/or reduction of staphylococcal populations. For example, a chimeric bacteriophage lysin was engineered and shown to effectively kill all strains of staphylococci tested including antibiotic resistant methicillin-resistant S. Aureus and VISA.

The present description relates to chimeric bacteriophage lysins useful for the identification and/or reduction of staphylococcal populations. For example, a chimeric bacteriophage lysin was engineered and shown to effectively kill all strains of staphylococci tested including antibiotic resistant methicillin-resistant S. Aureus and VISA.

Provided herein are methods for using RNAi molecules targeting an Inhibitor of Apoptosis (IAP) gene for controlling Coleopteran insects, methods for producing RNAi molecules targeting IAP, and compositions comprising RNAi molecules targeting IAP.

The invention provides a method of increasing an amount of oral immunoglobulin A (IgA) and/or inhibiting oral pathogens in a subject in need thereof, which utilizes a composition including a therapeutically effective amount of probiotics as an effective ingredient. The probiotics include Lactobacillus plantarum LPL28, which can efficiently increase the amount of oral IgA and/or inhibit the oral pathogens, and thus have a potential to prevent teeth cavities and/or periodontal diseases.

Disclosed is the hypolipidemic potential of Bacillus coagulans. More specifically the invention discloses the cholesterol lowering potential of Bacillus coagulans MTCC 5856 and therapeutic/biological indications thereof.

The present invention relates to methods for the screening, identification and/or application of microorganisms and/or compositions of use in imparting beneficial properties to plants, and microorganisms and compositions identified therefrom.

The present invention relates to methods for the screening, identification and/or application of microorganisms and/or compositions of use in imparting beneficial properties to plants, and microorganisms and compositions identified therefrom.